Veracyte

Develops genomic tests for cancer diagnosis

San Francisco, California, United States

About Veracyte

Veracyte specializes in cancer diagnostics by developing advanced genomic tests that assist in the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples, such as nasal swabs or tissue biopsies, providing crucial insights into the presence and progression of cancer. This allows healthcare providers, including hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve patient outcomes and enhance the efficiency of cancer treatment through accurate and early diagnosis.

San Francisco, CaliforniaHeadquarters
2008Year Founded
$69.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Performance Bonus
Stock Options
Remote Work Options

Risks

Potential bias in tests due to initial development on White American males.
MRD assay launch in 2026 may face acceptance challenges from payers.
ClearLab launch could encounter regulatory hurdles affecting market penetration.

Differentiation

Veracyte specializes in non-invasive genomic tests for early cancer detection.
The Decipher Prostate genomic classifier aids in prostate cancer prognosis.
Veracyte's nasal swab test improves early lung cancer risk assessment.

Upsides

AI-driven genomic testing enhances precision in diverse populations.
Board expansion with Brent Shafer and Tom Miller fosters strategic innovation.
Recognition as a top workplace attracts talent and drives innovation.

Funding

Total raised$69.36 M
Latest valuation$140.00 M
StageIPO
POST IPO EQUITY
4/30/2024
N/A
IPO
9/30/2013
$65
GROWTH EQUITY VC
9/30/2012
$15
SERIES A
11/30/2006
N/A
$1.50 M